We are live on ! Find out more
IDNA icon

iShares Genomics Immunology and Healthcare ETF
IDNA

75 hedge funds and large institutions have $46.1M invested in iShares Genomics Immunology and Healthcare ETF in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.78% more ownership

Funds ownership: 29.91% → 32.69% (+2.8%)

8% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 13

0% more funds holding

Funds holding: 75 → 75 (0)

0% less capital invested

Capital invested by funds: $46.2M → $46.1M (-$153K)

9% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 22

Holders
75
Holders Change
–
Holders Change %
0%
% of All Funds
1.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
20
Reduced
22
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WBG
Wharton Business Group
Pennsylvania
+$3.81M
2
Bank of America
Bank of America
North Carolina
+$1.32M
3
Ameriprise
Ameriprise
Minnesota
+$852K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$771K
5
PP
Prudential plc
United Kingdom
+$726K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.75M
2
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$774K
3
Jane Street
Jane Street
New York
-$730K
4
Nomura Asset Management
Nomura Asset Management
Japan
-$568K
5
Citadel Advisors
Citadel Advisors
Florida
-$394K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCA
26
Cora Capital Advisors
New Jersey
$380K +$409K +16,334 New
AWM
27
Apollon Wealth Management
South Carolina
$371K -$235K -9,394 -37%
LRPA
28
L. Roy Papp & Associates
Arizona
$362K -$162K -6,490 -29%
CPRC
29
Consolidated Portfolio Review Corp
New York
$355K +$382K +15,258 New
WGCA
30
Wolf Group Capital Advisors
Virginia
$340K -$16.3K -650 -4%
Walleye Capital
31
Walleye Capital
New York
$292K +$314K +12,538 New
BTWM
32
Baker Tilly Wealth Management
Wisconsin
$283K -$25.4K -1,015 -8%
Goldman Sachs
33
Goldman Sachs
New York
$273K -$243K -9,719 -45%
NSAM
34
North Star Asset Management
Wisconsin
$258K – – –
IWC
35
Integrated Wealth Concepts
Massachusetts
$253K +$272K +10,876 New
CA
36
Cetera Advisors
Colorado
$242K -$15.9K -636 -6%
Wells Fargo
37
Wells Fargo
California
$239K +$81.9K +3,272 +47%
WCM
38
Wealthcare Capital Management
Virginia
$214K +$17.6K +705 +8%
ASN
39
Advisory Services Network
Georgia
$126K +$89.2K +3,567 +195%
IA
40
IFP Advisors
Florida
$119K -$43.1K -1,722 -26%
Bank of Montreal
41
Bank of Montreal
Ontario, Canada
$77.1K -$27K -1,080 -25%
VWM
42
Venturi Wealth Management
Texas
$49.8K +$53.5K +2,138 New
PFM
43
Phillips Financial Management
Indiana
$37.4K – – –
CSPIA
44
Cary Street Partners Investment Advisory
Virginia
$37.2K +$3K +120 +8%
BFEC
45
Benjamin F. Edwards & Company
Missouri
$37K +$39.5K +1,580 New
S
46
SignatureFD
Georgia
$34.9K – – –
BFPW
47
BOK Financial Private Wealth
Colorado
$31K – – –
SS
48
Sunbelt Securities
Texas
$26.1K +$28.5K +1,140 New
AIC
49
Archer Investment Corporation
Indiana
$23.3K – – –
PCFFS
50
Pacific Center for Financial Services
California
$19.6K +$21K +840 New
1
2
3 4

IDNA Hedge Fund Activity: Q1 2023 in Review

75 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q1 2023, worth a combined $46.1M — down 0.33% from $46.2M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IDNA positions and 13 closed out — a net gain of 1 holder — while 20 added to existing stakes and 22 trimmed.

The largest buyer was Wharton Business Group, adding an estimated $3.81M. The largest seller was Morgan Stanley, cutting an estimated $1.75M.

  • 75 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $46.1M of iShares Genomics Immunology and Healthcare ETF stock for Q1 2023, down 0.33% quarter-over-quarter.
  • 14 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q1 2023 and 13 closed out, a net change of +1 holder.
  • The largest iShares Genomics Immunology and Healthcare ETF buyer in Q1 2023 was Wharton Business Group, an estimated $3.81M added.
  • The largest iShares Genomics Immunology and Healthcare ETF seller in Q1 2023 was Morgan Stanley, an estimated $1.75M sold.

Based on aggregated 13F filings for Q1 2023.